Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn

M. Saif
{"title":"Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn","authors":"M. Saif","doi":"10.17140/POJ-4-E012","DOIUrl":null,"url":null,"abstract":"The American Cancer Society’s estimates that 57,600 people (30,400 men and 27,200 women) will be diagnosed with pancreatic cancer in the United States for 2020 and approximately 47,050 people (24,640 men and 22,410 women) will die of pancreatic cancer in 2020.1 Despite advances in first-line therapy such as gemcitabine/nab-paclitaxel and fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) in advanced pancreatic cancer (aPC), median overall survival remains less than 12-months.2","PeriodicalId":20001,"journal":{"name":"Pancreas (Fairfax, Va.)","volume":"54 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreas (Fairfax, Va.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17140/POJ-4-E012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

The American Cancer Society’s estimates that 57,600 people (30,400 men and 27,200 women) will be diagnosed with pancreatic cancer in the United States for 2020 and approximately 47,050 people (24,640 men and 22,410 women) will die of pancreatic cancer in 2020.1 Despite advances in first-line therapy such as gemcitabine/nab-paclitaxel and fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) in advanced pancreatic cancer (aPC), median overall survival remains less than 12-months.2
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胰腺癌的突出结果:我们吸取了什么教训
美国癌症协会估计,到2020年,美国将有57600人(30400名男性和27200名女性)被诊断为胰腺癌,到2020年将有大约47050人(24640名男性和22410名女性)死于胰腺癌。尽管吉西他滨/nab-紫杉醇、氟尿嘧啶、亚叶酸钙、奥沙利铂和伊立替康(FOLFIRINOX)等一线治疗方法在晚期胰腺癌(aPC)中取得了进展,但中位总生存期仍不到12个月
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn. Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer. Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1